Skip to main content

OpenEvidence

Category: AI in Healthcare

A specialized AI-powered clinical decision support platform that provides physicians with real-time, evidence-based, and peer-reviewed answers to complex medical questions. OpenEvidence was founded in 2021. The company is led by Daniel Nadler. Based in Miami, USA. Team size: 11-50. Total funding raised: ~$325M total. Latest round: Series D ($250M, Jan 2026 at $12B valuation). Key investors include ["Mayo Clinic","Spark Capital","Daniel Nadler"].

Founded
2021
Headquarters
Miami, USA
Team size
11-50
Total funding
~$325M total

Value proposition

Eliminates medical information overload by synthesizing vast amounts of peer-reviewed literature into actionable clinical insights, reducing physician burnout and improving diagnostic accuracy.

Products and solutions

["OpenEvidence Clinical Search Engine","USMLE-Validated Medical LLM","Evidence-Based Citation System (Primary Source Linking)","Institutional Clinical Decision Support API"]

Unique value

It is the first AI system to pass the United States Medical Licensing Examination (USMLE) and is specifically engineered to prioritize peer-reviewed medical literature over general web data to prevent hallucinations.

Target customer

Physicians, clinicians, medical researchers, healthcare systems, and medical students.

Industries served

["Healthcare","Medical Education","Biotechnology","Pharmaceuticals"]

Technology advantage

Utilizes proprietary 'grounded' AI models that link every response to high-quality medical evidence; benefits from a strategic validation partnership with the Mayo Clinic and the leadership of Daniel Nadler, who previously scaled Kensho Technologies.

How they differentiate

OpenEvidence differentiates through its 'grounded' AI architecture that eliminates hallucinations by citing every sentence to peer-reviewed medical literature. Unlike legacy tools like UpToDate which rely on human-authored summaries, OpenEvidence provides real-time synthesis of the entire PubMed database and was the first AI to pass the USMLE.

Main competitors

["UpToDate (Wolters Kluwer)","Glass Health","Consensus","Perplexity (Medical)"]

Key partnerships

["Mayo Clinic (Strategic partner for clinical validation and development)","Harvard University (Academic and research collaboration)","Major U.S. Healthcare Systems"]

Notable customers

["Mayo Clinic","Harvard Medical School","Major U.S. Health Systems"]

Major milestones

["First AI system to pass the United States Medical Licensing Examination (USMLE)","Established strategic validation partnership with Mayo Clinic Platform","Founder Daniel Nadler named to TIME100 Health 2024","Achieved 'Unicorn' status with a $1.2B valuation in January 2026"]

Growth metrics

Used by clinicians across more than 2,000 healthcare institutions; valuation reached $1.2B as of early 2026.

Market positioning

Premium AI-native clinical decision support (CDS) platform for healthcare professionals and institutional health systems.

Geographic focus

Global (Primary focus on North America and European medical markets)

Patents and IP

Proprietary medical-grade LLM architectures and citation-verification algorithms (Specific public patent filings not disclosed).

About Daniel Nadler

Dr. Daniel Nadler is a serial entrepreneur and the founder of OpenEvidence. He previously founded Kensho Technologies, a leading provider of AI and machine learning to the financial industry, which was acquired by S&P Global in 2018 for approximately $550 million—at the time, the largest AI acquisition in history. He holds a PhD from Harvard University and has been recognized as a global leader in applying specialized AI to high-stakes industries.

Official website: